James Rucker

7.8k total citations · 3 hit papers
115 papers, 3.9k citations indexed

About

James Rucker is a scholar working on Clinical Psychology, Pharmacology and Organic Chemistry. According to data from OpenAlex, James Rucker has authored 115 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Clinical Psychology, 42 papers in Pharmacology and 30 papers in Organic Chemistry. Recurrent topics in James Rucker's work include Psychedelics and Drug Studies (46 papers), Cannabis and Cannabinoid Research (36 papers) and Chemical synthesis and alkaloids (30 papers). James Rucker is often cited by papers focused on Psychedelics and Drug Studies (46 papers), Cannabis and Cannabinoid Research (36 papers) and Chemical synthesis and alkaloids (30 papers). James Rucker collaborates with scholars based in United Kingdom, United States and Canada. James Rucker's co-authors include Camilla Day, David Taylor, Michael Bloomfield, James A. Rickard, Amanda Feilding, David Erritzøe, Mendel Kaelen, Mark Bolstridge, Robin Carhart‐Harris and David Nutt and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

James Rucker

101 papers receiving 3.8k citations

Hit Papers

Psilocybin with psychological support for treatment-resis... 2016 2026 2019 2022 2016 2017 2022 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
    2016 1.0k citations James Rucker, David Taylor et al. profile →
  2. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
    2017 646 citations James Rucker, David Taylor et al. profile →
  3. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
    2022 139 citations James Rucker, Anthony J. Cleare et al. Frontiers in Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Rucker United Kingdom 26 2.8k 1.7k 1.3k 632 314 115 3.9k
Kim P. C. Kuypers Netherlands 39 2.9k 1.0× 1.3k 0.8× 1.7k 1.3× 1.1k 1.7× 439 1.4× 127 4.3k
Michael Kometer Switzerland 22 2.4k 0.9× 1.2k 0.7× 1.5k 1.2× 265 0.4× 491 1.6× 37 3.1k
Frederick S. Barrett United States 39 4.7k 1.7× 2.7k 1.6× 2.1k 1.7× 483 0.8× 758 2.4× 80 6.1k
Robin Carhart‐Harris United Kingdom 25 3.2k 1.2× 1.6k 0.9× 1.5k 1.2× 263 0.4× 544 1.7× 65 3.9k
Dráulio Barros de Araújo Brazil 29 2.2k 0.8× 826 0.5× 1.1k 0.9× 450 0.7× 712 2.3× 110 3.6k
Leor Roseman United Kingdom 36 5.0k 1.8× 2.6k 1.5× 2.5k 1.9× 411 0.7× 865 2.8× 76 5.9k
Yasmin Schmid Switzerland 27 2.1k 0.7× 846 0.5× 1.2k 1.0× 446 0.7× 398 1.3× 57 2.7k
Patrick C. Dolder Switzerland 27 2.0k 0.7× 1.1k 0.6× 1.3k 1.0× 189 0.3× 415 1.3× 43 2.5k
Christopher Timmermann United Kingdom 24 2.1k 0.7× 1.1k 0.6× 943 0.7× 172 0.3× 357 1.1× 60 2.5k
Katherine A. MacLean United States 22 2.5k 0.9× 868 0.5× 723 0.6× 192 0.3× 268 0.9× 30 3.4k

Countries citing papers authored by James Rucker

Since Specialization
Citations

This map shows the geographic impact of James Rucker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Rucker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Rucker more than expected).

Fields of papers citing papers by James Rucker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Rucker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Rucker. The network helps show where James Rucker may publish in the future.

Co-authorship network of co-authors of James Rucker

This figure shows the co-authorship network connecting the top 25 collaborators of James Rucker. A scholar is included among the top collaborators of James Rucker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Rucker. James Rucker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kerr‐Gaffney, Jess, et al.. (2025). Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review. Journal of Psychopharmacology. 39(10). 1103–1113.
2.
Brown, Sam P., Michael Kelleher, Luke Mitcheson, et al.. (2025). Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review. Addiction. 4 indexed citations
3.
Roberts, Claire, Mathieu Seynaeve, Fiona Dunbar, et al.. (2024). Rapid antidepressant effect of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in treatment-resistant patients: a phase 2a open label study. Neuroscience Applied. 3. 104765–104765.
4.
Cleare, Anthony J., et al.. (2024). Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis”. [J. Affect. Disord., 322 (2023), 194–204]. Journal of Affective Disorders. 348. 409–409. 1 indexed citations
5.
Bocharova, Mariia, Tim Mantingh, James Rucker, et al.. (2024). Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & Therapeutics. 258. 108641–108641. 8 indexed citations
6.
Li, Adam Y., Simon Erridge, Carl Holvey, et al.. (2024). UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients. International Clinical Psychopharmacology. 39(6). 350–360. 1 indexed citations
7.
8.
9.
Rucker, James. (2023). Evidence versus expectancy: the development of psilocybin therapy. BJPsych Bulletin. 48(2). 110–117. 6 indexed citations
10.
Rucker, James, et al.. (2023). Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of Affective Disorders. 326. 18–25. 19 indexed citations
11.
Erridge, Simon, Carl Holvey, Ross Coomber, et al.. (2023). Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry. Brain and Behavior. 13(7). e3072–e3072. 14 indexed citations
12.
Erridge, Simon, et al.. (2023). A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance. Neuropsychopharmacology Reports. 44(1). 129–142. 11 indexed citations
13.
Erridge, Simon, Carl Holvey, Ross Coomber, et al.. (2023). An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry. Neuropsychopharmacology Reports. 43(4). 616–632. 6 indexed citations
14.
Erridge, Simon, Michal Kawka, Carl Holvey, et al.. (2022). An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry. Cannabis and Cannabinoid Research. 8(3). 557–566. 26 indexed citations
15.
Erridge, Simon, Michal Kawka, Carl Holvey, et al.. (2021). UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Review of Clinical Pharmacology. 15(4). 473–485. 24 indexed citations
16.
17.
Rucker, James & Allan H. Young. (2021). Psilocybin: From Serendipity to Credibility?. Frontiers in Psychiatry. 12. 659044–659044. 23 indexed citations
18.
Tufte, Kristin, et al.. (2007). Toward Systematic Improvement of Data Quality in Portland, Oregon, Regional Transportation Archive Listing. Transportation Research Board 86th Annual MeetingTransportation Research Board. 1 indexed citations
19.
Takeuchi, Akinori, Alex Vesely, James Rucker, et al.. (2000). A Simple “New” Method to Accelerate Clearance of Carbon Monoxide. American Journal of Respiratory and Critical Care Medicine. 161(6). 1816–1819. 34 indexed citations
20.
Fisher, Joseph A., James Rucker, Alex Vesely, et al.. (1999). Isocapnic Hyperpnea Accelerates Carbon Monoxide Elimination. American Journal of Respiratory and Critical Care Medicine. 159(4). 1289–1292. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim P. C. Kuypers Breakdown of academic impact, for papers by Michael Kometer Breakdown of academic impact, for papers by Frederick S. Barrett Breakdown of academic impact, for papers by Robin Carhart‐Harris Breakdown of academic impact, for papers by Dráulio Barros de Araújo Breakdown of academic impact, for papers by Leor Roseman Breakdown of academic impact, for papers by Yasmin Schmid Breakdown of academic impact, for papers by Patrick C. Dolder Breakdown of academic impact, for papers by Christopher Timmermann Breakdown of academic impact, for papers by Katherine A. MacLean
Rankless by CCL
2026